Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021231803 - BINDING MOLECULES FOR COVID-19 TREATMENT

Publication Number WO/2021/231803
Publication Date 18.11.2021
International Application No. PCT/US2021/032348
International Filing Date 13.05.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61K 39/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
C07K 14/165 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
CPC
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
22from camelids, e.g. camel, llama or dromedary
C07K 2317/569
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • ABCORE OP, LLC [US]/[US]
  • BARRACLOUGH, David [US]/[US]
  • JOHNSON, Jennifer [US]/[US]
  • DWYER, Mary [US]/[US]
Inventors
  • BARRACLOUGH, David
  • JOHNSON, Jennifer
  • DWYER, Mary
Agents
  • BUCKLEY, Kevin W.
Priority Data
63/024,49713.05.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) BINDING MOLECULES FOR COVID-19 TREATMENT
(FR) MOLÉCULES DE LIAISON POUR LE TRAITEMENT DE LA COVID-19
Abstract
(EN) The invention herein related to methods and compositions for treating coronavirus infections. The methods comprise peptides that bind to receptors important in disease progression, thus attenuating the disease.
(FR) L'invention concerne des procédés et des compositions pour le traitement d'infections à coronavirus. Les procédés comprennent des peptides qui se lient à des récepteurs importants dans la progression de la maladie, atténuant ainsi la maladie.
Latest bibliographic data on file with the International Bureau